CpG DNA, liposome and refined antigen oral cholera vaccine.
An oral cholera vaccine made up of three Vibrio cholerae antigens, i.e. lipopolysaccharide (LPS), recombinant toxin co-regulated pili (rTcpA) and heat-treated cholera toxin (H-CT) has been developed in six different formulations. Eight-week-old Wistar rats were divided into nine groups and immunized as follows: the first group received the oral vaccine 1 consisting of the three antigens (LPS, rTcpA and H-CT) associated with a liposome (L) and bacterial CpG-DNA (ODN#1826). The rats of groups 2 and 3 received oral vaccines 2 and 3 consisting of the liposome-associated three antigens with and without non-bacterial CpG-DNA (ODN#1982), respectively. Rats of groups 4 received oral vaccine 4 consisting of the three antigens mixed with the ODN#1826, similar to vaccine 1, but without liposome. Rats of groups 5 and 6 received oral vaccines 5 and 6 consisting of the three antigens with and without ODN#1982, respectively, similar to vaccines 2 and 3, but without liposome. Rats of groups 7, 8 and 9 received oral placebos, namely liposomes (L), ODN#1826 (CpG), and vaccine diluent, i.e. 5% NaHCO3 solution, respectively. All vaccines were given in three doses at 14-day intervals. It was found that the combination of liposome and ODN#1826 in vaccine 1 evoked the highest immune response to V. cholerae antigen compared to other vaccine formulations and placebos, as measured by the appearance of antigen-specific antibody-producing cells in the intestinal lamina propria. The immunogenicity according to the magnitude of the immune response was: V1>V2=V3>V4>V5=V6>V7=V8=V9. The results of this study indicate that CpG-DNA and liposome are effective mucosal adjuvants for an oral cholera vaccine prepared from refined V. cholerae antigens and their combination seems to be synergistic. The potential role of liposome as a vaccine delivery vehicle has been confirmed.
Leelawongtawon
Ratree
R
Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Somroop
Srinuan
S
Chaisri
Urai
U
Tongtawe
Pongsri
P
Chongsa-nguan
Manas
M
Kalambaheti
Thareerat
T
Tapchaisri
Pramuan
P
Pichyangkul
Sathit
S
Sakolvaree
Yuwaporn
Y
Kurazono
Hisao
H
Hayashi
Hideo
H
Chaicumpa
Wanpen
W
D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000942:Antigens, Bacterial / Q000008:administration & dosage* / Q000276:immunology; D002771:Cholera / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000008:administration & dosage* / Q000276:immunology; D018899:CpG Islands / Q000235:genetics*; D004247:DNA / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization; D008081:Liposomes / Q000008:administration & dosage* / Q000276:immunology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D014734:Vibrio cholerae / Q000276:immunology
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D022121:Cholera Vaccines; D008081:Liposomes; D004247:DNA